Autoantibodies pp 183-189 | Cite as

Analysis of Anti-C1q Autoantibodies by Western Blot

  • Anci Verlemyr
  • Lennart Truedsson
  • Lillemor SkattumEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1901)


Anti-C1q autoantibodies may be found in many conditions, most commonly in systemic lupus erythematosus (SLE) and hypocomplementemic urticarial vasculitis syndrome (HUVS), and are diagnostic markers as well as disease activity markers in lupus nephritis. Sera from patients with SLE and HUVS show partly distinct autoantibody reactivities to separated protein chains B and C of the first component of complement, C1q. These different binding specificities can be detected by Western blot analysis of the autoantibodies under reducing conditions. Results may help clinicians to differentiate between SLE and HUVS.

Key words

Anti-C1q autoantibodies Western blot C1q protein chains B and C Systemic lupus erythematosus Hypocomplementemic urticarial vasculitis syndrome 



We wish to acknowledge the work of those who, together with Lennart Truedsson, first published the use of Western blot analysis of anti-C1q antibodies [16]; Ulla Mårtensson, the late Anders Sjöholm, and the late Anna-Brita Laurell.


  1. 1.
    Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT (2015) Complement system part I—molecular mechanisms of activation and regulation. Front Immunol 6:262PubMedPubMedCentralGoogle Scholar
  2. 2.
    Thielens NM, Tedesco F, Bohlson SS et al (2017) C1q: a fresh look upon an old molecule. Mol Immunol 89:73–83CrossRefGoogle Scholar
  3. 3.
    Beurskens FJ, van Schaarenburg RA, Trouw LA (2015) C1q, antibodies and anti-C1q autoantibodies. Mol Immunol 68(1):6–13CrossRefGoogle Scholar
  4. 4.
    Orbai AM, Truedsson L, Sturfelt G et al (2015) Anti-C1q antibodies in systemic lupus erythematosus. Lupus 24(1):42–49CrossRefGoogle Scholar
  5. 5.
    Wisnieski JJ, Naff GB (1989) Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum 32(9):1119–1127CrossRefGoogle Scholar
  6. 6.
    Skattum L, Mårtensson U, Sjöholm AG (1992) Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies. J Intern Med 242(6):455–464CrossRefGoogle Scholar
  7. 7.
    Yoshikura N, Kimura A, Hayashi Y, Inuzuka T (2017) Anti-C1q autoantibodies in patients with neuromyelitis optica spectrum disorders. J Neuroimmunol 310:150–157CrossRefGoogle Scholar
  8. 8.
    Stojan G, Petri M (2016) Anti-C1q in systemic lupus erythematosus. Lupus 25(8):873–877CrossRefGoogle Scholar
  9. 9.
    Saadoun D, Sadallah S, Trendelenburg M et al (2006) Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol 145(2):308–312CrossRefGoogle Scholar
  10. 10.
    Sturfelt G, Truedsson L (2012) Complement in the immunopathogenesis of rheumatic disease. Nat Rev Rheumatol 8(8):458–468CrossRefGoogle Scholar
  11. 11.
    Wisnieski JJ, Jones SM (1992) Comparison of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus. J Immunol 148(5):1396–1403PubMedGoogle Scholar
  12. 12.
    Agnello V, Koffler D, Eisenberg JW et al (1971) C1q precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J Exp Med 134(3):228–241PubMedPubMedCentralGoogle Scholar
  13. 13.
    Marder RJ, Burch FX, Schmid FR et al (1978) Low molecular weight C1q-precipitins in hypocomplementemic vasculitis-urticaria syndrome: partial purification and characterization as immunoglobulin. J Immunol 121(2):613–618PubMedGoogle Scholar
  14. 14.
    Uwatoko S, Mannik M (1988) Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. J Clin Invest 82(3):816–824CrossRefGoogle Scholar
  15. 15.
    Trouw LA, Groeneveld TW, Seelen MA et al (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114(5):679–688CrossRefGoogle Scholar
  16. 16.
    Mårtensson U, Sjöholm AG, Sturfelt G et al (1992) Western blot analysis of human IgG reactive with the collagenous portion of C1q: evidence of distinct binding specificities. Scand J Immunol 35(6):735–744CrossRefGoogle Scholar
  17. 17.
    Sjöwall C, Mandl T, Skattum L, Olsson M, Mohammad AJ (2018). Epidemiology of hypocomplementaemic urticarial vasculitis (anti-C1q vasculitis). Rheumatology(Oxford) 57(8):1400–1407Google Scholar
  18. 18.
    Mårtensson U, Thiel S, Jensenius JC, Sjöholm AG (1996) Human autoantibodies against Clq: lack of cross reactivity with the collectins mannan-binding protein, lung surfactant protein A and bovine conglutinin. Scand J Immunol 43(3):314–320CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Anci Verlemyr
    • 1
  • Lennart Truedsson
    • 2
  • Lillemor Skattum
    • 2
    • 1
    Email author
  1. 1.Clinical Immunology and Transfusion MedicineRegion SkåneSweden
  2. 2.Department of Laboratory Medicine, Section of Microbiology, Immunology and GlycobiologyLund UniversityLundSweden

Personalised recommendations